Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

15 Jan 2007 12:52

Phytopharm PLC15 January 2007 Phytopharm plc Annual Information Update Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 December 2006, the following information has been published or made available to the public during the 12 months ended 12 January 2007, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances. 1. Announcements made via Regulatory Information Services All documents listed below were published via a regulatory information service on the dates indicated: Date of publication Title 10 January 2007 Director/PDMR shareholding10 January 2007 Director/PDMR shareholding 9 January 2007 Board changes19 December 2006 Notification of total voting rights10 November 2006 Director/PDMR shareholding 8 November 2006 Preliminary results for the year ended 31 August 2006 1 November 2006 Block listing interim review27 October 2006 Notification of results18 September 2006 Block listing interim review 5 September 2006 Board changes21 July 2006 Board appointment 5 June 2006 Board appointment19 May 2006 Holding(s) in company11 May 2006 Director/PDMR shareholding11 May 2006 Director/PDMR shareholding 8 May 2006 Interim results 3 May 2006 Block listing interim review27 April 2006 Holding(s) in company27 April 2006 Holding(s) in company26 April 2006 Advisor appointment24 April 2006 Product launch10 April 2006 Research update30 March 2006 Notice of results17 March 2006 Block listing interim review30 January 2006 Second price monitoring extension30 January 2006 Price monitoring extension24 January 2006 Results of AGM 2. Documents despatched to shareholders The following documents have been despatched by the Company to holders of its securities during the year: 27 December 2006 - Annual Report 2006 1 June 2006 - Interim Report 2006 3. Documents field at Companies House The Company has submitted the following Filings to Companies House: 11 January 2007 Form 288(a) Appointment of Director Mr Piers Morgan11 January 2007 Form 288(b) Terminating appointment of Director - Dr Richard Dixey 5 December 2006 Form 363 Annual Return 6 September 2006 Form 288(b) Terminating appointment of Director - Dr Trevor Flanagan 6 September 2006 Form 288(b) Terminating appointment of Director - Mr Gordon Stevens24 July 2006 Form 288(a) Appointment of Director - Dr Peter Blower 8 June 2006 Form 288(a) Appointment of Director - Mr Alexander Morrison24 January 2006 Registration of special resolutions passed at AGM Copies of these documents can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries@companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk The Company's annual report and accounts 2006 (published on 28 December 2006) and Interim Report 2005 (published on 1 June 2006) can be found on the Company's website as can the Interim Results announcement for the six months ended 28 February 2006 (published on 8 May 2006) and the Preliminary Results Announcement (published on 8 November 2006), The Company's website is www.phytopharm.com. Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HY, United Kingdom) during normal business hours or by request from the Company Secretary. For further information, please contact: Zoe McGowan, Company Secretary Phytopharm plc Tel No: +44 (0)1480 437697 Further information, about Phytopharm can be found on the Company's website www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options
30th Jan 201710:28 amRNSResult of AGM
17th Jan 20174:09 pmRNSDirector/PDMR Shareholding
17th Jan 20177:00 amRNSAppointment of Giulio Cerroni as CEO
16th Jan 20172:00 pmRNSAnnual Report and Accounts and Notice of AGM
13th Jan 20173:25 pmRNSHolding(s) in Company
12th Jan 20172:56 pmRNSHolding(s) in Company
4th Jan 20173:43 pmRNSIssue of 590,093 Deferred Consideration Shares
23rd Dec 20167:00 amRNSBuyback and Cancellation of Deferred Shares
20th Dec 20167:00 amRNSFull Year Results
16th Nov 20167:00 amRNSParticipation in major EU partnership (ROADMAP)
21st Oct 20167:00 amRNSPre-Close Trading Update
20th Oct 20167:00 amRNS$1.2m contract with new global pharma customer
19th Oct 20167:00 amRNSIXICO presents at CAMD regulatory workshop
10th Oct 20167:00 amRNSEUR1m funding as a partner in major EU consortium
3rd Oct 20167:00 amRNSAppointment of Shore Capital as Nominated Adviser
3rd Oct 20167:00 amRNSAppointment of Shore Capital
26th Sep 20165:14 pmRNSDirector/PDMR Shareholding
26th Sep 20161:58 pmRNSExercise of Share Options
16th Sep 20167:00 amRNSBoard changes
13th Sep 20167:00 amRNSPresentation of Assessa® PML at ECTRIMS
29th Jul 201610:25 amRNSWeb-Based Technology Improves Paediatric ADHD Care
7th Jun 20167:00 amRNSHalf Yearly Report to 31 March 2016
2nd Jun 20167:00 amRNSCygnus joins Dementias Platform UK
4th Apr 20167:00 amRNSConsortium and Five Year Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.